Logo image of PLRX

PLIANT THERAPEUTICS INC (PLRX) Stock Fundamental Analysis

USA - NASDAQ:PLRX - US7291391057 - Common Stock

1.5 USD
+0.05 (+3.45%)
Last: 10/2/2025, 8:00:01 PM
1.49 USD
-0.01 (-0.67%)
After Hours: 10/2/2025, 8:00:01 PM
Fundamental Rating

1

PLRX gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 196 industry peers in the Pharmaceuticals industry. PLRX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PLRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PLRX had negative earnings in the past year.
PLRX had a negative operating cash flow in the past year.
In the past 5 years PLRX always reported negative net income.
In the past 5 years PLRX always reported negative operating cash flow.
PLRX Yearly Net Income VS EBIT VS OCF VS FCFPLRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

PLRX has a Return On Assets of -69.03%. This is in the lower half of the industry: PLRX underperforms 66.84% of its industry peers.
PLRX's Return On Equity of -94.04% is in line compared to the rest of the industry. PLRX outperforms 42.35% of its industry peers.
Industry RankSector Rank
ROA -69.03%
ROE -94.04%
ROIC N/A
ROA(3y)-39.89%
ROA(5y)-35.54%
ROE(3y)-47.53%
ROE(5y)-41.22%
ROIC(3y)N/A
ROIC(5y)N/A
PLRX Yearly ROA, ROE, ROICPLRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for PLRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PLRX Yearly Profit, Operating, Gross MarginsPLRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K -10K

More info and screens

4

2. Health

2.1 Basic Checks

PLRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PLRX has more shares outstanding than it did 1 year ago.
PLRX has more shares outstanding than it did 5 years ago.
PLRX has a worse debt/assets ratio than last year.
PLRX Yearly Shares OutstandingPLRX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
PLRX Yearly Total Debt VS Total AssetsPLRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

Based on the Altman-Z score of -4.50, we must say that PLRX is in the distress zone and has some risk of bankruptcy.
PLRX has a Altman-Z score (-4.50) which is in line with its industry peers.
PLRX has a Debt/Equity ratio of 0.14. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of PLRX (0.14) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Altman-Z -4.5
ROIC/WACCN/A
WACC10.22%
PLRX Yearly LT Debt VS Equity VS FCFPLRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

PLRX has a Current Ratio of 12.99. This indicates that PLRX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PLRX (12.99) is better than 86.22% of its industry peers.
A Quick Ratio of 12.99 indicates that PLRX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 12.99, PLRX belongs to the best of the industry, outperforming 86.22% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.99
Quick Ratio 12.99
PLRX Yearly Current Assets VS Current LiabilitesPLRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

0

3. Growth

3.1 Past

PLRX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10.03%.
PLRX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-10.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.83%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

PLRX is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.90% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y22.99%
EPS Next 2Y20.14%
EPS Next 3Y17.14%
EPS Next 5Y6.9%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PLRX Yearly Revenue VS EstimatesPLRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2025 2026 2027 2028 2029 2030 2031 2032 20M 40M 60M 80M 100M
PLRX Yearly EPS VS EstimatesPLRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PLRX Price Earnings VS Forward Price EarningsPLRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PLRX Per share dataPLRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

PLRX's earnings are expected to grow with 17.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.14%
EPS Next 3Y17.14%

More info and screens

0

5. Dividend

5.1 Amount

PLRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLIANT THERAPEUTICS INC

NASDAQ:PLRX (10/2/2025, 8:00:01 PM)

After market: 1.49 -0.01 (-0.67%)

1.5

+0.05 (+3.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners84.8%
Inst Owner Change-10.61%
Ins Owners2.46%
Ins Owner Change0%
Market Cap92.08M
Analysts69.47
Price Target3.23 (115.33%)
Short Float %6.28%
Short Ratio4.5
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.31%
Min EPS beat(2)-24.53%
Max EPS beat(2)-0.1%
EPS beat(4)2
Avg EPS beat(4)-0.63%
Min EPS beat(4)-24.53%
Max EPS beat(4)18.2%
EPS beat(8)5
Avg EPS beat(8)2.55%
EPS beat(12)8
Avg EPS beat(12)3.26%
EPS beat(16)10
Avg EPS beat(16)2.73%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)7.09%
PT rev (3m)-33.83%
EPS NQ rev (1m)-1.68%
EPS NQ rev (3m)-8.02%
EPS NY rev (1m)-1.16%
EPS NY rev (3m)-3.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.42
P/tB 0.42
EV/EBITDA N/A
EPS(TTM)-3.4
EYN/A
EPS(NY)-1.93
Fwd EYN/A
FCF(TTM)-2.78
FCFYN/A
OCF(TTM)-2.76
OCFYN/A
SpS0
BVpS3.58
TBVpS3.58
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -69.03%
ROE -94.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.89%
ROA(5y)-35.54%
ROE(3y)-47.53%
ROE(5y)-41.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 78.46%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.99
Quick Ratio 12.99
Altman-Z -4.5
F-Score3
WACC10.22%
ROIC/WACCN/A
Cap/Depr(3y)109.27%
Cap/Depr(5y)114.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.83%
EPS Next Y22.99%
EPS Next 2Y20.14%
EPS Next 3Y17.14%
EPS Next 5Y6.9%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-4.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.93%
EBIT Next 3Y8.75%
EBIT Next 5YN/A
FCF growth 1Y-60.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.67%
OCF growth 3YN/A
OCF growth 5YN/A